glycine has been researched along with Malignant Melanoma in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "N-Diazoacetyl derivatives of glycine and phenylalanine show antitumor activity in mice bearing P388 leukemia or B16 melanoma." | 7.66 | Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. ( Baldini, L; Giraldi, T; Sava, G, 1982) |
| "Malignant melanoma is a highly aggressive tumor resistant to chemotherapy." | 5.46 | Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017) |
| " Our objective was to precisely assess changes in α-syn levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines following acute exposure to pesticides (rotenone, paraquat, maneb, and glyphosate) using Western blot and flow cytometry." | 3.79 | Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. ( Andrieu, T; Baron, T; Bétemps, D; Chorfa, A; Hogeveen, K; Lazizzera, C; Morignat, E, 2013) |
| "N-Diazoacetyl derivatives of glycine and phenylalanine show antitumor activity in mice bearing P388 leukemia or B16 melanoma." | 3.66 | Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. ( Baldini, L; Giraldi, T; Sava, G, 1982) |
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
| "Malignant melanoma is a highly aggressive tumor resistant to chemotherapy." | 1.46 | Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017) |
| "Six CDKN2A families had pancreatic cancer." | 1.31 | Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. ( Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA, 2000) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "The putative metastasis suppressor genes, NME1(nm23-1) and NME2(nm23-2), were examined in a model system we developed to approximate the dissemination of melanoma from a primary skin tumor." | 1.29 | Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials. ( Backer, JM; Hamby, CV; Mendola, CE; Potla, L; Stafford, G, 1995) |
| "Many BRMs have been used in treatment of melanoma, e." | 1.28 | Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. ( Hayasaka, K; Ishihara, K; Yamazaki, N, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (21.43) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 1 |
| Liu, X | 1 |
| Chen, Y | 1 |
| Xu, R | 1 |
| He, S | 1 |
| Pizzato Scomazzon, S | 1 |
| Riccio, A | 1 |
| Santopolo, S | 1 |
| Lanzilli, G | 1 |
| Coccia, M | 1 |
| Rossi, A | 1 |
| Santoro, MG | 1 |
| Yan, C | 1 |
| Saleh, N | 1 |
| Yang, J | 2 |
| Nebhan, CA | 1 |
| Vilgelm, AE | 1 |
| Reddy, EP | 1 |
| Roland, JT | 1 |
| Johnson, DB | 1 |
| Chen, SC | 1 |
| Shattuck-Brandt, RL | 1 |
| Ayers, GD | 1 |
| Richmond, A | 1 |
| Saei, A | 1 |
| Palafox, M | 1 |
| Benoukraf, T | 1 |
| Kumari, N | 1 |
| Jaynes, PW | 1 |
| Iyengar, PV | 1 |
| Muñoz-Couselo, E | 1 |
| Nuciforo, P | 1 |
| Cortés, J | 1 |
| Nötzel, C | 1 |
| Kumarakulasinghe, NB | 1 |
| Richard, JLC | 1 |
| Bin Adam Isa, ZF | 1 |
| Pang, B | 1 |
| Guzman, M | 1 |
| Siqin, Z | 1 |
| Yang, H | 1 |
| Tam, WL | 1 |
| Serra, V | 1 |
| Eichhorn, PJA | 1 |
| Mu, LM | 1 |
| Liu, L | 1 |
| Liu, R | 1 |
| Du, YF | 1 |
| Luo, Q | 1 |
| Xu, JR | 1 |
| Xie, Y | 1 |
| Lu, WL | 1 |
| Chorfa, A | 1 |
| Bétemps, D | 1 |
| Morignat, E | 1 |
| Lazizzera, C | 1 |
| Hogeveen, K | 1 |
| Andrieu, T | 1 |
| Baron, T | 1 |
| Fortes, C | 1 |
| Mastroeni, S | 1 |
| Segatto M, M | 1 |
| Hohmann, C | 1 |
| Miligi, L | 1 |
| Bakos, L | 1 |
| Bonamigo, R | 1 |
| Cheewinthamrongrod, V | 1 |
| Kageyama, H | 1 |
| Palaga, T | 1 |
| Takabe, T | 1 |
| Waditee-Sirisattha, R | 1 |
| Suarez-Kelly, LP | 1 |
| Kemper, GM | 1 |
| Duggan, MC | 1 |
| Stiff, A | 1 |
| Noel, TC | 1 |
| Markowitz, J | 1 |
| Luedke, EA | 1 |
| Yildiz, VO | 1 |
| Yu, L | 1 |
| Jaime-Ramirez, AC | 1 |
| Karpa, V | 1 |
| Zhang, X | 1 |
| Carson, WE | 1 |
| Muqaku, B | 1 |
| Eisinger, M | 1 |
| Meier, SM | 1 |
| Tahir, A | 1 |
| Pukrop, T | 1 |
| Haferkamp, S | 1 |
| Slany, A | 1 |
| Reichle, A | 1 |
| Gerner, C | 1 |
| Jiang, BP | 1 |
| Zhang, L | 1 |
| Guo, XL | 1 |
| Shen, XC | 1 |
| Wang, Y | 1 |
| Zhu, Y | 1 |
| Liang, H | 1 |
| Venè, R | 1 |
| Castellani, P | 1 |
| Delfino, L | 1 |
| Lucibello, M | 1 |
| Ciriolo, MR | 1 |
| Rubartelli, A | 1 |
| Miao, Y | 1 |
| Jalili, A | 1 |
| Wagner, C | 1 |
| Pashenkov, M | 1 |
| Pathria, G | 1 |
| Mertz, KD | 1 |
| Widlund, HR | 1 |
| Lupien, M | 1 |
| Brunet, JP | 1 |
| Golub, TR | 1 |
| Stingl, G | 1 |
| Fisher, DE | 1 |
| Ramaswamy, S | 1 |
| Wagner, SN | 1 |
| Yamashina, S | 1 |
| Ikejima, K | 1 |
| Rusyn, I | 2 |
| Sato, N | 1 |
| Sava, G | 1 |
| Giraldi, T | 1 |
| Baldini, L | 1 |
| Thomasset, N | 1 |
| Quash, GA | 1 |
| Doré, JF | 1 |
| Hamby, CV | 1 |
| Mendola, CE | 1 |
| Potla, L | 1 |
| Stafford, G | 1 |
| Backer, JM | 1 |
| Kask, K | 1 |
| Berthold, M | 1 |
| Kahl, U | 1 |
| Nordvall, G | 1 |
| Bartfai, T | 1 |
| Ts'ao, C | 1 |
| Molteni, A | 1 |
| Taylor, JM | 1 |
| Rose, ML | 2 |
| Madren, J | 1 |
| Bunzendahl, H | 1 |
| Thurman, RG | 2 |
| Goldstein, AM | 1 |
| Struewing, JP | 1 |
| Chidambaram, A | 1 |
| Fraser, MC | 1 |
| Tucker, MA | 1 |
| Wheeler, MD | 1 |
| Ikejema, K | 1 |
| Enomoto, N | 1 |
| Stacklewitz, RF | 1 |
| Seabra, V | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Schemmer, P | 1 |
| Bradford, B | 1 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| Ishihara, K | 1 |
| Hayasaka, K | 1 |
| Yamazaki, N | 1 |
| Knudsen, BS | 1 |
| Harpel, PC | 1 |
| Nachman, RL | 1 |
| Pasztor, LM | 1 |
| Hu, F | 1 |
| Stankova, L | 1 |
| Bigley, R | 1 |
| Schulman, JD | 1 |
| Wrathall, JR | 1 |
| Silagi, S | 1 |
| Doores, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01205815] | 3,000 participants (Anticipated) | Observational | 2010-06-03 | Recruiting | |||
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
1 review available for glycine and Malignant Melanoma
| Article | Year |
|---|---|
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
27 other studies available for glycine and Malignant Melanoma
| Article | Year |
|---|---|
KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
Topics: Annexins; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Glycine; Histones; Humans; Jumo | 2022 |
The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Topics: Baculoviral IAP Repeat-Containing 3 Protein; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Tra | 2019 |
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Topics: Animals; Antineoplastic Agents; CD40 Antigens; Female; Glycine; Humans; Immune Checkpoint Inhibitors | 2021 |
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
Topics: Animals; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; F-Box-WD Repeat-Co | 2018 |
Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma.
Topics: Animals; Cancer Vaccines; Cytokines; Disease Models, Animal; Female; Glycine; Humans; Immunomodulati | 2019 |
Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.
Topics: alpha-Synuclein; Cell Death; Cell Line, Tumor; Cell Survival; Glycine; Glyphosate; Humans; Insectici | 2013 |
Occupational Exposure to Pesticides With Occupational Sun Exposure Increases the Risk for Cutaneous Melanoma.
Topics: Adult; Aged; Brazil; Case-Control Studies; Female; Fungicides, Industrial; Glycine; Glyphosate; Herb | 2016 |
DNA damage protecting and free radical scavenging properties of mycosporine-2-glycine from the Dead Sea cyanobacterium in A375 human melanoma cell lines.
Topics: Antioxidants; Cell Line, Tumor; Cyanobacteria; Cyclohexanols; DNA Damage; Free Radical Scavengers; G | 2016 |
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2016 |
Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma.
Topics: Asparagine; Biomarkers, Tumor; Blood Platelets; Cachexia; Calcium; Glycine; Humans; Melanoma; Metabo | 2017 |
Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma.
Topics: Animals; Cell Death; Cell Line, Tumor; Glycine; Humans; Hyaluronic Acid; Hyperthermia, Induced; Infr | 2017 |
The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets.
Topics: Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Cell Survival | 2011 |
Substitution of Gly with Ala enhanced the melanoma uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide.
Topics: alpha-MSH; Animals; Binding, Competitive; Cell Line, Tumor; Glycine; Inhibitory Concentration 50; Me | 2012 |
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Blotting, Western; Cell Line, Tumor; Cycl | 2012 |
Glycine as a potent anti-angiogenic nutrient for tumor growth.
Topics: Calcium; Cell Movement; Chloride Channels; Endothelium, Vascular; Glycine; Humans; In Vitro Techniqu | 2007 |
Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Glycine; Leukemia, Experimental; Melanoma; Mice; Neop | 1982 |
The differential contribution of arginase and transamidinase to ornithine biosynthesis in two achromic human melanoma cell lines.
Topics: Amidinotransferases; Arginase; Arginine; Cell Line; Glycine; Humans; Hydrogen-Ion Concentration; Mel | 1982 |
Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials.
Topics: Amino Acid Sequence; Animals; Base Sequence; Cell Line; Clone Cells; DNA Primers; Gene Expression; G | 1995 |
Delineation of the peptide binding site of the human galanin receptor.
Topics: Alanine; Amino Acid Sequence; Animals; Binding Sites; Cell Membrane; Cloning, Molecular; Conserved S | 1996 |
Injury-specific cytotoxic response of tumor cells and endothelial cells.
Topics: Animals; Cattle; Cells, Cultured; Chromium Radioisotopes; Endopeptidases; Endothelium, Vascular; Gly | 1996 |
Dietary glycine inhibits the growth of B16 melanoma tumors in mice.
Topics: Animals; Cell Division; Cell Line; Diet; Glycine; Melanoma; Mice; Neovascularization, Pathologic; Sk | 1999 |
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; G | 2000 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan.
Topics: Biological Factors; Biological Products; Cell Wall Skeleton; Cytokines; DNA, Bacterial; Glycine; Hum | 1989 |
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.
Topics: Animals; Cattle; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Extracellular Matrix; Glycine | 1987 |
8-Azaguanine-resistant melanoma cells in vitro and in vivo.
Topics: Aminopterin; Animals; Azaguanine; Bromodeoxyuridine; Cell Division; Cell Fusion; Cell Line; Drug Res | 1974 |
Altered amino acid concentrations accompanying suppression of malignancy of mouse melanoma cells by 5-bromodeoxyuridine.
Topics: Alanine; Amino Acids; Animals; Asparagine; Bromodeoxyuridine; Cells, Cultured; Glutamates; Glutamine | 1974 |